You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 24, 2025

Patent: 10,493,125


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,493,125
Title:Co-agonists of the glucagon and GLP-1 receptors
Abstract: Co-agonists of the glucagon and GLP-1 receptors are described.
Inventor(s): Palani; Anandan (Bridgewater, NJ), Carrington; Paul E. (San Mateo, CA), Pessi; Antonello (Rome, IT), Lahm; Armin (Rome, IT), Bianchi; Elisabetta (Pomezia, IT), Demartis; Anna (Pomezia, IT)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:15/774,622
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,493,125

Introduction

Patents are a cornerstone of innovation, providing inventors and companies with the exclusive rights to their inventions. However, the patent landscape is complex and evolving, influenced by various factors including legal changes, technological advancements, and demographic disparities. This article will provide a comprehensive and critical analysis of the claims and the broader patent landscape, using the example of United States Patent 10,493,125, although the specific details of this patent will not be the primary focus.

The Gender Patenting Gap

One of the significant issues in the patent landscape is the gender patenting gap. Women hold a disproportionately small share of patents. According to the Institute for Women’s Policy Research, women's representation among patent holders has increased, but at the current rate, gender patent equity is more than 75 years away[1].

Regional Disparities in Patenting

Patenting activity is not evenly distributed across the United States. High patenting intensity is concentrated in areas such as the coasts, Texas, and parts of the Great Lakes and Rocky Mountains. This geographic disparity highlights the need for federal initiatives to improve regional innovative capacity, which could drive economic growth and higher living standards more uniformly across the country[5].

Diversity of U.S. Inventors

The diversity of inventors is another critical aspect of the patent landscape. Studies have shown that patenting activity varies significantly according to an individual’s gender, race, and socioeconomic background. Men are much more likely to be named as inventors on patents than women, and there is a lack of data on the demographic information of inventors, which hampers policy solutions aimed at increasing diversity[5].

The Leahy-Smith America Invents Act (AIA)

The 2011 Leahy-Smith America Invents Act (AIA) is a landmark legislation that has significantly impacted the patent landscape. The AIA created the Patent Trial and Appeal Board (PTAB), which hears administrative challenges to the validity of patents. This has provided a faster and less expensive alternative to judicial proceedings for challenging patent validity, though it has also been criticized for making it too easy to challenge patents, potentially stifling innovation[3].

Patent Trial and Appeal Board (PTAB)

PTAB plays a crucial role in maintaining patent quality by providing a mechanism to challenge patents that should not have been issued. However, critics argue that PTAB's processes create uncertainty in patent rights and discourage investments in patent-intensive industries. The balance between improving patent quality and ensuring the stability of patent rights remains a contentious issue[3].

Increasing Complexity of Patent Applications

The number of patent applications and the number of claims per application have been increasing steadily. This trend is driven by technological innovation and facilitated by technologies such as word processing and remote electronic database searching. The complexity of patent applications, with some having thousands of claims, necessitates automated systems to manage and analyze these claims efficiently[2].

Automated Patent Claims Analysis

To address the growing complexity, systems like the Patent Matrix software have been developed. These systems automate the import of patent claims, parse the claims into their hierarchy, and provide compression and expansion functionality. Such tools are essential for keeping pace with the growing volume of patent prior art and ensuring that patent claims are thoroughly reviewed[2].

Patent Search Services

Effective patent search services are vital for identifying prior art, determining patentability, and assessing the validity of patents. These services help in making informed decisions about whether to proceed with a patent filing or to revise claims. Comprehensive global prior art searches are crucial for defending against patent infringement assertions and for negotiating licensing agreements[4].

Economic Implications of Patenting Disparities

The disparities in patenting activity have significant economic implications. Closing the gender and racial patenting gaps could potentially lead to a two-percentage-point increase in the U.S. gross domestic product per capita. However, quantifying these impacts is complex, and more data is needed to understand the full economic effects of these disparities[5].

Policy Considerations for Promoting Diversity

To promote greater diversity in the innovation ecosystem, Congress could consider several policy changes. Collecting demographic data from inventors, such as gender, race, and military or veteran status, could provide valuable insights into the scope of inequities in the patent system. Federal initiatives to improve regional innovative capacity could also help in creating a more diverse and inclusive innovation environment[5].

Challenges and Opportunities

The patent landscape is marked by both challenges and opportunities. The increasing complexity of patent applications and the need for efficient review processes present significant challenges. However, advancements in technology and the creation of new legal frameworks also offer opportunities for innovation and growth.

Key Takeaways

  • Gender Patenting Gap: Women hold a disproportionately small share of patents, with gender patent equity more than 75 years away at the current rate of progress.
  • Regional Disparities: Patenting activity is concentrated in specific regions, highlighting the need for federal initiatives to improve regional innovative capacity.
  • Diversity of Inventors: Patenting activity varies significantly by gender, race, and socioeconomic background.
  • AIA and PTAB: The Leahy-Smith America Invents Act created PTAB, which has both improved patent quality and raised concerns about patent stability.
  • Increasing Complexity: The number of patent applications and claims is increasing, necessitating automated systems for efficient review.
  • Economic Implications: Addressing patenting disparities could have significant economic benefits.

FAQs

Q: What is the current state of the gender patenting gap in the United States? A: Women hold only a small share of patents, and at the current rate of progress, gender patent equity is more than 75 years away[1].

Q: How has the Leahy-Smith America Invents Act impacted the patent landscape? A: The AIA created the Patent Trial and Appeal Board (PTAB), which provides a faster and less expensive way to challenge patent validity, though it has also been criticized for creating uncertainty in patent rights[3].

Q: What are the economic implications of disparities in patenting activity? A: Closing the gender and racial patenting gaps could potentially lead to a two-percentage-point increase in the U.S. gross domestic product per capita, though quantifying these impacts is complex[5].

Q: How are automated systems helping in the patent application process? A: Automated systems like the Patent Matrix software help in importing, parsing, and analyzing patent claims, making it easier to manage the growing complexity of patent applications[2].

Q: Why is collecting demographic data from inventors important? A: Collecting demographic data can provide valuable insights into the scope of inequities in the patent system and help policymakers develop solutions to increase diversity in the innovation ecosystem[5].

Sources

  1. Institute for Women’s Policy Research. "The Gender Patenting Gap."
  2. Google Patents. "US20110138338A1 - Patent Claims Analysis System and Method."
  3. Congressional Research Service. "The Patent Trial and Appeal Board and Inter Partes Review."
  4. Clarivate. "Patent Search Services - Patent Validity Search."
  5. Congressional Research Service. "Equity in Innovation: Trends in U.S. Patenting and Inventor Diversity."

More… ↓

⤷  Try for Free

Details for Patent 10,493,125

ApplicantTradenameBiologic IngredientDosage FormBLAApproval DatePatent No.Expiredate
Eli Lilly And Company HUMALOG insulin lispro Injection 020563 June 14, 1996 10,493,125 2035-12-09
Eli Lilly And Company HUMALOG insulin lispro Injection 020563 August 06, 1998 10,493,125 2035-12-09
Eli Lilly And Company HUMALOG insulin lispro Injection 020563 September 06, 2007 10,493,125 2035-12-09
Eli Lilly And Company HUMALOG insulin lispro Injection 020563 June 06, 2017 10,493,125 2035-12-09
Eli Lilly And Company HUMALOG insulin lispro Injection 020563 November 15, 2019 10,493,125 2035-12-09
Sanofi-aventis U.s. Llc LANTUS insulin glargine Injection 021081 April 20, 2000 10,493,125 2035-12-09
>Applicant>Tradename>Biologic Ingredient>Dosage Form>BLA>Approval Date>Patent No.>Expiredate
Showing 1 to 6 of 6 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.